![Hiroaki Shizuya](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hiroaki Shizuya
Oprichter bij Aliva Biopharmaceuticals, Inc.
Profiel
Hiroaki Shizuya is the founder of Aliva Biopharmaceuticals, Inc. (founded in 2002) and Ablexis LLC (founded in 2009).
He was a member of the California Institute of Technology.
He earned a doctorate degree from Keio University.
Actieve functies van Hiroaki Shizuya
Bedrijven | Functie | Begin |
---|---|---|
Aliva Biopharmaceuticals, Inc.
![]() Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Oprichter | 03-06-2010 |
Eerdere bekende functies van Hiroaki Shizuya
Bedrijven | Functie | Einde |
---|---|---|
California Institute of Technology
![]() California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | Corporate Officer/Principal | - |
Ablexis LLC
![]() Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Oprichter | - |
Opleiding van Hiroaki Shizuya
Keio University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Aliva Biopharmaceuticals, Inc.
![]() Aliva Biopharmaceuticals, Inc. Pharmaceuticals: GenericHealth Technology Aliva Biopharmaceuticals, Inc. is building the next generation animal systems for accurate prediction in human drug profiling at the pre-clinical stage with its BAC (Bacterial Artificial Chromosome) based genome engineering technology. In addition, Aliva's technology platform provides animal models that mimic serious human functional and infectious diseases for assessing effectiveness of new therapeutics prior to selecting a lead compound for Phase I testing. This technology will also be applicable for assessing the drug response of people with small genetic differences, which would allow matching drug candidates with appropriate patient populations. | Health Technology |
Ablexis LLC
![]() Ablexis LLC Packaged SoftwareTechnology Services Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA. | Technology Services |